Latest news with #RelonchemLimited
Business Upturn
30-05-2025
- Business
- Business Upturn
Marksans Pharma's subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution
By Aman Shukla Published on May 30, 2025, 09:24 IST Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Metformin Hydrochloride 500mg/5ml Oral Solution. This regulatory approval enables Relonchem to market and distribute the product in the UK. Metformin Hydrochloride is a widely prescribed medication used for the management of type 2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. In the exchange filing, the company shared, 'Marksans Pharma Limited (Reuters: Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.' This approval marks a significant milestone for Marksans Pharma as it continues to strengthen its presence in regulated markets like the UK. The company's focus on expanding its product portfolio with value-added generic formulations aligns with its strategic growth vision. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
19-05-2025
- Business
- Business Upturn
Marksans Pharma's UK arm gets marketing approval for Sennosides 7.5 mg tablets
By Aditya Bhagchandani Published on May 19, 2025, 13:27 IST Shares of Marksans Pharma could remain in focus after the company announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization for Sennosides 7.5 mg tablets from the UK Medicines & Healthcare Products Regulatory Agency (MHRA). This regulatory clearance marks a significant step in the company's product expansion in the UK pharmaceutical market. Sennosides are typically used as a laxative in various therapeutic segments, and the approval strengthens Marksans' position in the gastrointestinal treatment category. Marksans Pharma, headquartered in Mumbai, engages in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets. Its manufacturing facilities in India, the USA, and the UK are approved by top regulatory bodies, including USFDA, UKMHRA, and Australian TGA. The company's product portfolio spans major therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
